Mediating Role of Gut Microbiota in the Regulation of Colorectal Cancer Risk in the Context of Time-restricted Eating and Calorie Restriction

限时饮食和热量限制背景下肠道微生物群在结直肠癌风险调节中的中介作用

基本信息

项目摘要

PROJECT ABSTRACT The goal of this Diversity Supplement is to extend the significance and innovation of the Parent grant by examining the effect of time-restricted eating (TRE) and daily calorie restriction (CR) on the gut microbiota (GM) and host-microbial interactions relevant to the prevention of colorectal cancer (CRC), the third most incident cancer in the United States. The Diversity Supplement will also provide essential training in cancer prevention to a promising Hispanic woman and Early-Stage Career Investigator, Dr. Beatriz Peñalver Bernabé. Obesity is a major modifiable lifestyle risk factor for CRC. TRE is emerging as an alternative approach to managing weight that involves simply watching the clock and eating for 4-10 hours daily, thus restricting the body’s exposure to nutrients for extended periods of time. TRE demonstrates excellent adherence as it is simple and omits burdensome calorie counting, a hallmark of traditional daily CR. The GM can produce beneficial metabolites, such anti-inflammatory butyrate, or improve gut integrity by promoting mucus production, but a dysregulated GM can lead to increase colonic levels of pro-inflammatory and cancer-promoting metabolites. Existing studies on the effects of TRE on the GM are limited in scope and methodology due to small samples sizes, short duration, use of low-resolution methods that fail to examine changes in microbial metabolic function, and lack of a robust assessment of host-microbial interactions in response to TRE. Further, the differential effects of TRE versus CR on the GM and the relevance to colonic carcinogenesis remains unknown. We hypothesize that both TRE and CR will promote a GM environment less permissive of colonic carcinogenesis and that TRE will be superior due to differences in nutrient exposures, a downstream effect of the shortened eating window. Further, we surmise that systems-level approaches, such as network analysis, can identify the key communications between the host and microbial metabolic and colon genetic networks that play mechanistic roles in CRC risk and prevention. Levering the infrastructure of the Parent grant, the proposed Diversity Supplement will use high-resolution methods, such as metagenomics and metabolomics, to characterize GM composition and metabolic function and host systemic metabolism. Statistical and network approaches will be employed to integrate these multi- omics data and colonic transcriptional profiles to determine the effect of TRE and CR on GM and host-microbial interactions. We aim to examine the microbial-regulated metabolite signatures and host-microbial interactions in response to TRE and daily CR while promoting and enhancing diversity among cancer prevention researchers. The Diversity Supplement will provide needed insight into the modulation of the GM and host-microbial interactions in response to TRE and CR and its relevance to the prevention of colorectal carcinogenesis.
项目摘要 这种多样性补充的目标是通过以下方式扩大父母补助金的意义和创新 研究限时进食(TRE)和每日卡路里限制(CR)对肠道微生物群(GM)的影响 和与预防结直肠癌(CRC)相关的宿主-微生物相互作用, 癌症在美国多样性补充方案还将提供预防癌症方面的基本培训 一位有前途的西班牙裔女性,早期职业调查员,比阿特丽斯·佩纳尔弗·伯纳贝博士。肥胖是 一个主要的可改变的生活方式的风险因素为CRC。TRE正在成为管理体重的替代方法 这包括简单地看时钟和每天吃4-10小时,从而限制身体暴露于 长期的营养素。TRE展示了出色的粘附性,因为它简单且省略了 繁琐的卡路里计算,这是传统每日CR的标志。转基因可以产生有益的代谢物, 这类抗炎丁酸盐,或通过促进粘液产生来改善肠道完整性,但GM失调 会导致结肠中促炎和促癌代谢物的水平增加。现有研究 由于样本量小,持续时间短, 使用低分辨率的方法,无法检查微生物代谢功能的变化, 对TRE响应的宿主-微生物相互作用的评估。此外,TRE与CR的差异效应 对转基因和结肠癌的相关性仍然未知。我们假设TRE和 CR将促进一个不太允许结肠癌发生的GM环境,TRE将是上级的, 营养暴露的差异,缩短进食窗口的下游效应。此外,我们还发现 系统级方法(如网络分析)可以识别主机之间的关键通信 以及微生物代谢和结肠遗传网络,在CRC风险和预防中发挥机械作用。 勒韦林母公司赠款的基础设施,拟议的多样性补充将使用高分辨率 表征GM组成和代谢功能的方法,例如宏基因组学和代谢组学 和宿主的全身代谢。将采用统计和网络方法来整合这些多方面的信息, 组学数据和结肠转录谱,以确定TRE和CR对GM和宿主微生物的影响 交互.我们的目的是研究微生物调节的代谢物特征和宿主-微生物相互作用 响应TRE和每日CR,同时促进和增强癌症预防研究人员的多样性。 多样性补充将提供所需的深入了解调制的转基因和宿主微生物 TRE和CR的相互作用及其与预防结直肠癌发生的相关性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lisa Tussing-Humphreys其他文献

Lisa Tussing-Humphreys的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lisa Tussing-Humphreys', 18)}}的其他基金

Effects of Time-restricted Eating versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers among Adults with Obesity
限时饮食与每日持续热量限制对肥胖成人体重和结直肠癌风险标志物的影响
  • 批准号:
    10304332
  • 财政年份:
    2021
  • 资助金额:
    $ 22.29万
  • 项目类别:
Effects of Time-restricted Eating versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers among Adults with Obesity
限时饮食与每日持续热量限制对肥胖成人体重和结直肠癌风险标志物的影响
  • 批准号:
    10676824
  • 财政年份:
    2021
  • 资助金额:
    $ 22.29万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 22.29万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 22.29万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 22.29万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 22.29万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 22.29万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 22.29万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 22.29万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 22.29万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 22.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了